| 臺大學術典藏 |
2018-09-10T14:53:14Z |
High serum levels of vascular endothelial growth Factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy
|
Cheng, Jason Chia-Hsien;Graber, Madeline S.;Hsu, Feng-Ming;Tsai, Chiao-Ling;Castaneda, Leon;Lee, Jang-Ming;Chang, Daniel T.;Koong, Albert C.; Cheng, J.C.-H. and Graber, M.S. and Hsu, F.-M. and Tsai, C.-L. and Castaneda, L. and Lee, J.-M. and Chang, D.T. and Koong, A.C.; 成佳憲;李章銘;蔡巧琳;許峰銘; 成佳憲; Cheng, Jason Chia-Hsien; JANG-MING LEE; Ahn, Hyun-Soo; Graber, Madeline S.; Hsu, Feng-Ming; Tsai, Chiao-Ling; Castaneda, Leon; Lee, Jang-Ming; Chang, Daniel T.; Koong, Albert C. |
| 臺大學術典藏 |
2014 |
High serum levels of vascular endothelial growth Factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy
|
Cheng J.C.-H.;Graber M.S.;Hsu F.-M.;Tsai C.-L.;Castaneda L.;Jang-Ming Lee;Chang D.T.;Koong A.C.; Cheng J.C.-H.; Graber M.S.; Hsu F.-M.; Tsai C.-L.; Castaneda L.; JANG-MING LEE; Chang D.T.; Koong A.C. |
| 臺大學術典藏 |
2020-05-25T02:45:38Z |
High serum levels of vascular endothelial growth Factor-A and transforming growth factor-�]1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy
|
Graber M.S; Feng-Ming Hsu; Tsai C.-L; Castaneda L; Lee J.-M; Chang D.T; Koong A.C.; Cheng J.C.-H |
| 臺大學術典藏 |
2021-05-21T07:17:48Z |
High serum levels of vascular endothelial growth Factor-A and transforming growth factor-�]1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy
|
Cheng J.C.-H.; Graber M.S.; Hsu F.-M.; CHIAO-LING TSAI; Castaneda L.; Lee J.-M.; Chang D.T.; Koong A.C. |
| 臺大學術典藏 |
2018-09-10T18:00:57Z |
High serum lipopolysaccharide-binding protein level in chronic hepatitis C viral infection is reduced by anti-viral treatments
|
Nien, H.-C. and Hsu, S.-J. and Su, T.-H. and Yang, P.-J. and Sheu, J.-C. and Wang, J.-T. and Chow, L.-P. and Chen, C.-L. and Kao, J.-H. and Yang, W.-S.; JIN-CHUAN SHEU; LU-PING CHOW; WEI-SHIUNG YANG; TUNG-HUNG SU; JIA-HORNG KAO |
| 臺大學術典藏 |
2020-01-22T04:47:48Z |
High serum lipopolysaccharide-binding protein level in chronic hepatitis C viral infection is reduced by anti-viral treatments
|
Nien H.-C.;Hsu S.-J.;Su T.-H.;Yang P.-J.;Sheu J.-C.;Wang J.-T.;Lu-Ping Chow;Chen C.-L.;Kao J.-H.;Yang W.-S.; Nien H.-C.; Hsu S.-J.; Su T.-H.; Yang P.-J.; Sheu J.-C.; Wang J.-T.; LU-PING CHOW; Chen C.-L.; Kao J.-H.; Yang W.-S. |
| 臺大學術典藏 |
2022-01-25T03:25:12Z |
High serum lipopolysaccharide-binding protein level in chronic hepatitis C viral infection is reduced by anti-viral treatments
|
Nien H.-C.; Hsu S.-J.; Su T.-H.; Yang P.-J.; Sheu J.-C.; Wang J.-T.; Chow L.-P.; CHI-LING CHEN; Kao J.-H.; Yang W.-S. |
| 臺大學術典藏 |
2021-03-09T01:47:31Z |
High serum lipopolysaccharide-binding protein level in chronic hepatitis C viral infection is reduced by anti-viral treatments
|
Nien H.-C.; Hsu S.-J.; TUNG-HUNG SU; Yang P.-J.; Sheu J.-C.; Wang J.-T.; Chow L.-P.; Chen C.-L.; Kao J.-H.; Yang W.-S. |
| 臺大學術典藏 |
2021-09-04T06:11:06Z |
High serum lipopolysaccharide-binding protein level in chronic hepatitis C viral infection is reduced by anti-viral treatments
|
Nien H.-C.; Hsu S.-J.; Su T.-H.; Yang P.-J.; Sheu J.-C.; Wang J.-T.; Chow L.-P.; Chen C.-L.; JIA-HORNG KAO; Yang W.-S. |
| 臺大學術典藏 |
2022-01-13T08:46:00Z |
High serum lipopolysaccharide-binding protein level in chronic hepatitis C viral infection is reduced by anti-viral treatments
|
Nien H.-C.; Hsu S.-J.; Su T.-H.; PO-JEN YANG; Sheu J.-C.; Wang J.-T.; Chow L.-P.; Chen C.-L.; Kao J.-H.; Yang W.-S. |
